J. Andrew Berglund, University of Oregon (IMAGE) University of Oregon Caption Andrew Berglund, a member of the University of Oregon's Institute of Molecular Biology, studies myotonic dystrophy. His team has found an existing FDA-approved compound for a variety of diseases might be modified to treat RNA slicing defects that lead to the disease. Credit Photo by Jim Barlow Usage Restrictions None License Licensed content Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.